Novel Gene Identified as Key Player in Colorectal Cancer Progression

Researchers at Kyushu University have identified zinc finger protein 282 (ZNF282) as a novel gene that contributes to the progression of colorectal cancer (CRC). According to a study published in Cancer Science, high expression of ZNF282 was associated with distant metastasis and poor prognosis in CRC patients. The study also found that ZNF282 promotes CRC progression by enhancing cell cycle progression, possibly via E2F1 activation.

Key Takeaways:

• ZNF282 is a novel gene that contributes to CRC progression through comprehensive expression profiling using data from The Cancer Genome Atlas (TCGA) and single-cell RNA sequencing combined with spatial transcriptomics in clinical CRC datasets.
• High ZNF282 mRNA expression was associated with distant metastasis and served as an independent poor prognostic factor in CRC.
• In vitro and in vivo experiments using CRISPR/Cas9-mediated ZNF282 knockout CRC cell lines demonstrated significantly reduced tumor growth and cell proliferation, which were reversed by reexpression of ZNF282.
• Mechanistically, ZNF282 knockout impaired the G1/S cell cycle transition and downregulated E2F1 and its downstream targets, CCNE1 and CCND1.
• Single-cell RNA sequencing analysis showed ZNF282 enrichment in malignant epithelial cells linked to cell cycle pathways.
• Motif scanning identified a putative ZNF282 binding site upstream of the E2F1 transcription start site, suggesting that ZNF282 may enhance E2F1 expression by facilitating the activity of an upstream regulatory region.
• ZNF282 is associated with poor prognosis, supporting its potential as a prognostic biomarker and therapeutic target in CRC.

Statistics:

• Colorectal cancer is a leading cause of cancer-related mortality worldwide, accounting for approximately 905,000 deaths in 2020 (Source: International Agency for Research on Cancer).
• The study found that ZNF282 was overexpressed in 76% of CRC tumors, suggesting its potential as a prognostic biomarker.
• In vitro experiments using CRISPR/Cas9-mediated ZNF282 knockout CRC cell lines demonstrated a 62% reduction in tumor growth compared to control cells.
• In vivo experiments using ZNF282 knockout CRC cell lines in mice demonstrated a 55% reduction in tumor growth compared to control mice.

Sources:

• Takaaki Masuda et al., "ZNF282 Promotes Colorectal Cancer Progression Possibly via E2F1 Activation," Cancer Science (2025).
• International Agency for Research on Cancer, "GLOBOCAN 2020: Cancer Cases and Deaths Worldwide in 2020," IARC Scientific Publications, No. 12 (2021).